Clinical Trial Update: CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial at Beijing Tongren Hospital evaluating a CD19/CD22 bispecific CAR-T cell therapy for relapsed/refractory diffuse large B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CD19-CD22-bispecific CAR-T cell therapy

Snippet

Sponsor: Beijing Tongren Hospital | Conditions: Large B-Cell Lymphoma (LBCL) | Phase 2 | Status: ACTIVE_NOT_RECRUITING